Accounting errors impact on Parexel in 09
Accounting errors related to the purchase of ClinPhone reduced Parexel’s operating income by $15.9m (€11.2m) in fiscal 2009 and the impact of these charges will continue into the next year.
Accounting errors related to the purchase of ClinPhone reduced Parexel’s operating income by $15.9m (€11.2m) in fiscal 2009 and the impact of these charges will continue into the next year.
Gilead Sciences is laying off up to 66 people as it closes its offices in Boulder and Westminster, Colorado, US to consolidate its operations in California.
The EMEA has approved Patheon’s facility in Manati, Puerto Rico, allowing the CMO to import to Europe and improving its fortunes on the island that caused it financial problems in the past.
Light Sciences Oncology (LSO) has begun treating the first patient in a Phase I trial of Aptocine (alaporfin sodium), a drug activated by an LED device inserted into a tumour.